Amendments to the Claims:

This listing of claims will replace all prior versions and listing of claims in the application.

Please amend claims 5-8, 19-23, and 25-27 as follows:

Please cancel claim 24 without prejudice or disclaimer.

Please add new claims 28-30 as follows:

1 (original): A therapeutic agent for inhibiting vascularization comprising as the effective ingredient, a substance that inhibits the action due to CXCR4.

2 (original): A therapeutic agent for a solid cancer comprising as the effective ingredient, a substance that inhibits the action due to CXCR4.

3 (original): A therapeutic agent for a disease pathologically caused by neovascularization comprising as the effective ingredient, a substance that inhibits the action due to CXCR4.

4 (original): A therapeutic agent for repairing a tissue comprising as the effective ingredient, a substance that inhibits the action due to CXCR4.

5 (currently amended): The therapeutic agent according to [any of claims 1-4] claim 1, wherein the substance inhibits the [very] binding between SDF-1 and CXCR4.

6 (currently amended): The therapeutic agent according to [any of claims 1-4] claim 1, wherein the substance inhibits signaling from CXCR4 to nuclei.

7 (currently amended): The therapeutic agent according to [any of claims 1-4] claim 1, wherein the substance inhibits the [very] expression of CXCR4.

8 (currently amended): The therapeutic agent according to [any of claims 1-4] claim 1, wherein the substance inhibits the [very] expression of SDF-1.

9 (original): The therapeutic agent according to claim 5, wherein the substance inhibits SDF-1.

10 (original): The therapeutic agent according to claim 5, wherein the substance inhibits CXCR4.

11 (original): The therapeutic agent according to claim 9, wherein the substance inhibits CXCR4 in antagonistic competition with SDF-1.

12 (original): The therapeutic agent according to claim 9, wherein the substance inhibits SDF-1 from binding to CXCR4 by binding to SDF-1.

13 (original): The therapeutic agent according to claim 11, wherein the substance is one selected from the group consisting of a SDF-1-like protein, a fused protein of the foregoing protein with another peptide or polypeptide, a partial peptide of SDF-1, and a low molecular weight compound having a structure similar to a binding site of SDF-1.

14 (original): The therapeutic agent according to claim 12, wherein the substance is one selected from the group consisting of an anti-SDF-1 antibody, a fragment of said antibody possessing the activity of the anti-SDF-1 antibody, a fused protein possessing binding activity to SDF-1, a substance that induces a structural change in SDF-1, and a low molecular weight compound capable of binding to the CXCR4-binding site of SDF-1.

15 (original): The therapeutic agent according to claim 10, wherein the substance inhibits CXCR4 in antagonistic competition with CXCR4 for binding to SDF-1.

16 (original): The therapeutic agent according to claim 10, wherein the substance inhibits SDF-1 from binding to CXCR4 by binding to CXCR4.

17 (original): The therapeutic agent according to claim 15, wherein the substance is one selected from the group consisting of a soluble CXCR4 that antagonizes CXCR4 in the inhibition, a protein having a CXCR4-like structure, a fused protein of the foregoing protein with another peptide or polypeptide, a partial peptide of CXCR4, and a low molecular weight compound having a structure similar to a binding site of SDF-1.

18 (original): The therapeutic agent according to claim 16, wherein the substance is one selected from the group consisting of an anti-CXCR4 antibody, a fragment of said antibody possessing the activity of anti-CXCR4 antibody, a fused protein possessing a binding activity to CXCR4, a substance that induces a structural change in SDF-1, and a low molecular weight compound capable of binding to the SDF-1-binding site of CXCR4.

19 (currently amended): The therapeutic agent according to claim 6, wherein the substance is an inhibitor of a signaling system located downstream of a G protein-coupled protein and is one selected from the group consisting of a MAPK cascade inhibitor, a [phospholipase] phospholipase C (PLC) inhibitor, and a PI3 kinase inhibitor.

20 (currently amended): The therapeutic agent according to claim 7, wherein the substance is a substance that causes apparent disappearance of CXCR4 from cells by acting [on eell] on a cell membrane to vary fluidity thereof and to cause disappearance of CXCR4 from the cell membrane.

21 (currently amended): The therapeutic agent according to claim 7, wherein the substance is a substance that inhibits the [very] expression of CXCR4 and is one selected from the group consisting of an antigene, an antisense polynucleotide, and an antisense RNA expressed by an antisense vector, a ribosome, and an inhibitor against the expression control site

of CXCR4.

22 (currently amended): The therapeutic agent according to claim 8, wherein the substance is an antisense [for the inhibition of] polynucleotide capable of inhibiting the expression of SDF-1.

23 (currently amended): The therapeutic agent according to claim 8, wherein the substance [shows inhibition against] inhibits the expression control site of SDF-1.

24 (cancelled).

25 (currently amended): A method for treating a solid cancer comprising [using] administering a substance that inhibits the action due to CXCR4 to a mammal in need thereof.

26 (currently amended): A method for treating a disease pathologically caused by neovascularization comprising [using] administering a substance that inhibits the action due to CXCR4 to a mammal in need thereof.

27 (currently amended): A method for repairing a tissue comprising [using] administering a substance that inhibits the action due to CXCR4 to a mammal in need thereof.

28 (new): A method for suppressing vascularization comprising administering a substance that inhibits the action of CXCR4 in a mammal in need thereof, wherein the substance inhibits the binding between the ligand SDF-1 and the receptor CXCR4.

29 (new): A method for suppressing vascularization comprising administering a substance that inhibits the action of CXCR4 in a mammal in need thereof, wherein the substance inhibits signaling from CXCR4 to nuclei.

Attorney Docket 046124-5042-01 New Continuation Application Page 7

30 (new): A method for suppressing vascularization comprising administering a substance that inhibits the action of CXCR4 in a mammal in need thereof, wherein the substance inhibits the expression of SDF-1.